UNSPSC 51182058: Nandrolone decanoate

This classification denotes a therapeutic androgen with the molecular formula C28H44O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H45187T098, chemically known as estr-4-en-3-one, 17-beta-hydroxy-, decanoate but more generally known as nandrolone decanoate, which bears US NIH Compound Identifier 9677. European Medicines Agency schedules Nandrolone decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03384MIG.

Most nations, for tariff and trade purposes, schedule nandrolone decanoate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE DECANOATE remains US FDA's Preferred Term for this commodity. Nandrolone decanoate bears US NLM identifiers UMLS ID C0068395 and NCI Concept Code C1172. SMILES: CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C.

UNSPSC 51182058 Nandrolone decanoate is a Commodity code representing a specific pharmaceutical ingredient used primarily in clinical and institutional settings by state and local health systems, correctional facilities, and public health agencies. State and local governments procure nandrolone decanoate through cooperative purchasing vehicles and multi-source pharmaceutical contracts that consolidate demand across multiple jurisdictions and authorized wholesalers, reducing costs and standardizing supply chains for injectable pharmaceutical products. The work involves manufacturers or authorized vendors supplying products with certified National Drug Codes, full regulatory compliance (cGMP, FDA, and Drug Supply Chain Security Act), and distribution through contracted wholesalers to state and local healthcare facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products, with nandrolone decanoate included in the product portfolio. Proposals were due March 26, 2026, with evaluation weighted heavily toward price competitiveness (75 percent), compliance with administrative requirements and EDI capability (15 percent combined), and fixed pricing and administrative fee agreement (10 percent combined). Awarded vendors must maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability insurance. The contract term runs two years for new responders effective July 1, 2026, with optional extensions at MMCAP's discretion. The RFP identifies participating states including Minnesota and Oregon but does not disclose specific award values or budget allocations.